Clinical trials: AMD
Macular Edema, Retinal Vein Occlusion
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with retinal vein occlusion.
- Trial name
- NCT00168298
- Testing
- 700 µg Dexamethasone, 350 µg Dexamethasone
- Where
- 13 sites in United States, Brazil and 11 more
- Volunteers
- 668 people
- Sponsor
- Allergan
Macular Edema
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
- Trial name
- NCT01492400
- Testing
- dexamethasone Intravitreal Implant, ranibizumab
- Where
- 13 sites in United States, Belgium and 10 more
- Volunteers
- 363 people
- Sponsor
- Allergan
Pompe Disease
Extension Study for Patients Who Have Participated in a BMN 701 Study
This is a Phase 2 open-label, multiple dose study of BMN 701 administered by IV infusion every 2 weeks (qow) to patients with late-onset Pompe disease.
- Trial name
- NCT01435772
- Testing
- BMN 701
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 21 people
- Sponsor
- BioMarin Pharmaceutical
Retinal Vein Occlusion, Macular Oedema
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received…
- Trial name
- NCT01566526
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Belgium
- Volunteers
- 26 people
- Sponsor
- Allergan
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with…
- Trial name
- HAWK (NCT02307682)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Where
- United States
- Volunteers
- 1,775 people
- Sponsor
- Alcon Research
Neovascular Age-related Macular Degeneration
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity.
- Trial name
- MACURELI (NCT00549055)
- Testing
- Macugen
- Where
- 4 sites in Belgium
- Volunteers
- 38 people
- Sponsor
- Pfizer
Geographic Atrophy
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related…
- Trial name
- FILLY (NCT02503332)
- Testing
- Pegcetacoplan
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 246 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Age-Related Macular Degeneration
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis®…
- Trial name
- NCT03211234
- Testing
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Where
- 14 sites in United States, Philippines
- Volunteers
- 76 people
- Sponsor
- Santen Inc.
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects…
- Trial name
- NCT01940887
- Testing
- E10030, bevacizumab or aflibercept
- Where
- 207 sites in United States, Argentina and 20 more
- Volunteers
- 645 people
- Sponsor
- Ophthotech Corporation
Pompe Disease
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
- Trial name
- NCT02675465
- Testing
- ATB200, AT2221
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 29 people
- Sponsor
- Amicus Therapeutics
Macular Edema Secondary to Central Retinal Vein Occlusion
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.
- Trial name
- NCT00943072
- Testing
- VEGF Trap-Eye 2.0mg
- Where
- 61 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Regeneron Pharmaceuticals
Pompe Disease, Glycogen Storage Disease Type II (GSD-II)
Immune Tolerance Induction Study
An exploratory, open-labeled study of participants with Pompe disease, who had previously received Myozyme® (alglucosidase alfa) treatment, to evaluate the efficacy, safety and clinical benefit of 2 Immune Tolerance Induction…
- Conditions
- Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Glycogenesis 2 Acid Maltase Deficiency
- Trial name
- NCT00701701
- Testing
- Myozyme® (alglucosidase alfa)
- Where
- 5 sites in United States, Israel
- Volunteers
- 4 people
- Sponsor
- Genzyme, a Sanofi Company
Stargardt Disease
Safety and Efficacy of Emixustat in Stargardt Disease
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD
- Trial name
- SeaSTAR (NCT03772665)
- Testing
- Emixustat
- Where
- 29 sites in United States, Brazil and 9 more
- Volunteers
- 194 people
- Sponsor
- Kubota Vision Inc.
Age-Related Macular Degeneration
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
- Trial name
- NCT02914639
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Macular Degeneration
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye.
- Trial name
- NCT00658619
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 119 people
- Sponsor
- Allergan
Choroidal Neovascularization
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This multiple-center, multiple-dose and regimen, randomized, double-masked active comparator-controlled, double-masked, five parallel group, 36-week study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of…
- Trial name
- AVENUE (NCT02484690)
- Testing
- Faricimab, Ranibizumab
- Where
- 52 sites in United States
- Volunteers
- 273 people
- Sponsor
- Hoffmann-La Roche
Macular Edema, Retinal Vein Occlusion
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
This study will evaluate the safety and efficacy of a single intravitreal injection of AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion.
- Trial name
- NCT01027650
- Testing
- AGN208397 intravitreal injection, dexamethasone intravitreal implant
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 121 people
- Sponsor
- Allergan
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
- Trial name
- COMRADE-C (NCT01396083)
- Testing
- Ranibizumab
- Where
- 64 sites in Germany, Hungary and 2 more
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval (PTI) to participants…
- Trial name
- AVONELLE-X (NCT04777201)
- Testing
- Faricimab, Anti-VEGF Therapy
- Where
- 251 sites in United States, Argentina and 25 more
- Volunteers
- 1,036 people
- Sponsor
- Hoffmann-La Roche
Macular Degeneration
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT01134055
- Testing
- pazopanib eye drops, ranibizumab intravitreal injection
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 510 people
- Sponsor
- GlaxoSmithKline